Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 4/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 3/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3434595 | 0.79 | POLQ (0.47) | POLQHTR2AKDM1AHTR2CPDK2 | |
| SCHEMBL17030738 | 0.79 | MGLL (0.40) | POLQHTR2AKDM1AHTR2CPDK2 | |
| SCHEMBL12556951 | 0.79 | KDM1A (0.42) | POLQHTR2AKDM1AHTR2CPDK2 | |
| SCHEMBL13256367 | 0.79 | HTR2A (0.43) | POLQHTR2AKDM1AHTR2CPDK2 | |
| SCHEMBL18162314 | 0.79 | POLQ (0.47) | POLQHTR2AKDM1AHTR2CPDK2 | |
| SCHEMBL18161909 | 0.77 | KDM1A (0.43) | POLQHTR2AKDM1AHTR2CPDK2 | |
| SCHEMBL28294833 | 0.77 | KDM1A (0.43) | POLQHTR2AKDM1AHTR2CPDK2 | |
| SCHEMBL26020142 | 0.77 | SSTR4 (0.35) | HTR2AHTR2CPDK2 | |
| SCHEMBL13838866 | 0.77 | KDM1A (0.61) | POLQHTR2AKDM1AHTR2CPDK2 | |
| SCHEMBL3719147 | 0.76 | HTR2C (0.61) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TRPC5, TRPC1, GOT1 | POLQ 4151/4885HTR2A 1054/4885KDM1A 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.